OTTAWA, Dec. 22, 2017 — Avivagen Inc. (TSX-V:VIV) (OTC Pink:CHEXF) (“Avivagen” or the “Company”), a life sciences innovation company with a series of patent protected products that support and optimize human and animal health, announces the granting of 60,000 options to a corporation controlled by a director of the Company. These options are granted pursuant to a consulting agreement between the Company and such corporation.The options, which shall be vested over an eight-quarter period, are exercisable up to five years from the issuing date, and have a strike price of $0.90.Option grants are subject to the approval of the TSX Venture Exchange.About Avivagen
Avivagen Inc. is a public Company traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com.
Latest posts by Brad Bennett (see all)
- Basic Energy Services Reschedules Fourth Quarter And Year End 2017 Earnings Release To February 26 - February 19, 2018
- Car Covers Market Outlook to 2025: Emerging Trends and Will Generate New Growth Opportunities Status - February 19, 2018
- Twila True Fine Jewelry Debuts at New York Fashion Week With Legendary Designer Zang Toi. - February 19, 2018